We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Caffeine Levels Prove Diagnostic for Early Parkinson's Disease

By LabMedica International staff writers
Posted on 15 Jan 2018
Print article
Image: A three-dimensional (3D) structure of caffeine (Photo courtesy of Wikimedia Commons).
Image: A three-dimensional (3D) structure of caffeine (Photo courtesy of Wikimedia Commons).
A team of Japanese researchers demonstrated that serum caffeine and its metabolites were reliable biomarkers for detection of early Parkinson's disease (PD).

A 2013 paper evaluated a total of 13 articles involving 901,764 participants for coffee, eight articles involving 344,895 participants for tea, and seven articles involving 492,724 participants for caffeine. Results revealed a linear dose-relationship for decreased PD risk with tea and caffeine consumption, whereas the strength of protection reached a maximum at approximately three cups/day for coffee consumption overall.

Based on the established link between PD and caffeine, investigators at Juntendo University School of Medicine (Tokyo, Japan) conducted a study on 108 people who had Parkinson's disease for an average of about six years and 31 people of the same age who did not have the disease. Liquid chromatography–mass spectrometry was used to determine serum levels of caffeine and of 11 byproducts the body makes as it metabolizes caffeine. Participants were also tested for mutations in genes that can affect caffeine metabolism.

Results revealed that Parkinson's disease patients had significantly lower blood levels of caffeine and nine of the 11 caffeine byproducts. The caffeine level was an average of 79 picomoles per 10 microliters for people without Parkinson's disease, compared to 24 picomoles per 10 microliters for patients. Measurement of caffeine correctly identified patients with early PD with 98% accuracy. No differences were found in the activity of caffeine-related genes between the two groups.

Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD. This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies. "Previous studies have shown a link between caffeine and a lower risk of developing Parkinson's disease, but we have not known much about how caffeine metabolizes within the people with the disease," said contributing author Dr. Shinji Saiki, a researcher in neurology at Juntendo University School of Medicine.

The caffeine study was published in the January 3, 2018, online edition of the journal Neurology.

Related Links:
Juntendo University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more